Matches in SemOpenAlex for { <https://semopenalex.org/work/W1520073491> ?p ?o ?g. }
- W1520073491 endingPage "579" @default.
- W1520073491 startingPage "570" @default.
- W1520073491 abstract "Aldoxorubicin, a prodrug of doxorubicin, covalently binds to serum albumin, allowing for the administration of much higher doses of doxorubicin in a previous clinical study. The current phase 1B/2 study evaluated the safety of aldoxorubicin, including preliminary efficacy and safety of its maximum tolerated dose (MTD).Patients aged 18 to 70 years with recurrent/refractory malignant solid tumors received aldoxorubicin at a dose of 230 mg/m(2) , 350 mg/m(2) , or 450 mg/m(2) (170 mg/m(2) , 260 mg/m(2) , or 335 mg/m(2) doxorubicin equivalents, respectively) by intravenous infusion once every 21 days for up to 8 consecutive cycles.A total of 25 patients were enrolled, including 17 patients (68%) with advanced soft tissue sarcoma (STS). The MTD of aldoxorubicin was 350 mg/m(2) ; dose-limiting toxicities included grade 4 neutropenia and grade 3 febrile neutropenia (NCI CTCAE v4.0). Drug-related adverse events included myelosuppression, nausea, fatigue, alopecia, stomatitis, vomiting, and oropharyngeal pain. No clinically significant cardiac toxicities were reported. Seven patients (28%) had elevated serum troponin levels while taking part in the study, but these elevations were not clinically significant or associated with cardiac findings. A partial response was achieved in 20% of patients, and stable disease was reported in 40% of patients. The median progression-free survival was 4.80 months, and the median overall survival was 11.25 months. Among patients with STS who were treated at the MTD (13 patients), a partial response was achieved in 38% and stable disease in 46%; the median progression-free survival was 11.25 months and the median overall survival was 21.71 months.Aldoxorubicin at a dose of 350 mg/m(2) administered once every 21 days for up to 8 cycles was found to be acceptably safe and demonstrated preliminary efficacy in patients with advanced solid tumors, including STS. Further investigation of aldoxorubicin is ongoing." @default.
- W1520073491 created "2016-06-24" @default.
- W1520073491 creator A5000999149 @default.
- W1520073491 creator A5003116709 @default.
- W1520073491 creator A5005108766 @default.
- W1520073491 creator A5007128913 @default.
- W1520073491 creator A5008969784 @default.
- W1520073491 creator A5073241613 @default.
- W1520073491 creator A5073483457 @default.
- W1520073491 creator A5073906112 @default.
- W1520073491 date "2014-10-13" @default.
- W1520073491 modified "2023-10-04" @default.
- W1520073491 title "A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma" @default.
- W1520073491 cites W1828224642 @default.
- W1520073491 cites W1828438395 @default.
- W1520073491 cites W1895775305 @default.
- W1520073491 cites W2003743385 @default.
- W1520073491 cites W2008044750 @default.
- W1520073491 cites W2036336400 @default.
- W1520073491 cites W2038717222 @default.
- W1520073491 cites W2044934343 @default.
- W1520073491 cites W2045558406 @default.
- W1520073491 cites W2058337944 @default.
- W1520073491 cites W2066742760 @default.
- W1520073491 cites W2066908594 @default.
- W1520073491 cites W2079088649 @default.
- W1520073491 cites W2107318974 @default.
- W1520073491 cites W2111426313 @default.
- W1520073491 cites W2155765426 @default.
- W1520073491 cites W2163151049 @default.
- W1520073491 cites W225519924 @default.
- W1520073491 doi "https://doi.org/10.1002/cncr.29081" @default.
- W1520073491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25312684" @default.
- W1520073491 hasPublicationYear "2014" @default.
- W1520073491 type Work @default.
- W1520073491 sameAs 1520073491 @default.
- W1520073491 citedByCount "21" @default.
- W1520073491 countsByYear W15200734912015 @default.
- W1520073491 countsByYear W15200734912016 @default.
- W1520073491 countsByYear W15200734912017 @default.
- W1520073491 countsByYear W15200734912018 @default.
- W1520073491 countsByYear W15200734912019 @default.
- W1520073491 crossrefType "journal-article" @default.
- W1520073491 hasAuthorship W1520073491A5000999149 @default.
- W1520073491 hasAuthorship W1520073491A5003116709 @default.
- W1520073491 hasAuthorship W1520073491A5005108766 @default.
- W1520073491 hasAuthorship W1520073491A5007128913 @default.
- W1520073491 hasAuthorship W1520073491A5008969784 @default.
- W1520073491 hasAuthorship W1520073491A5073241613 @default.
- W1520073491 hasAuthorship W1520073491A5073483457 @default.
- W1520073491 hasAuthorship W1520073491A5073906112 @default.
- W1520073491 hasBestOaLocation W15200734911 @default.
- W1520073491 hasConcept C121332964 @default.
- W1520073491 hasConcept C121608353 @default.
- W1520073491 hasConcept C126322002 @default.
- W1520073491 hasConcept C136948725 @default.
- W1520073491 hasConcept C141071460 @default.
- W1520073491 hasConcept C142424586 @default.
- W1520073491 hasConcept C142724271 @default.
- W1520073491 hasConcept C197934379 @default.
- W1520073491 hasConcept C2776694085 @default.
- W1520073491 hasConcept C2776802502 @default.
- W1520073491 hasConcept C2777063308 @default.
- W1520073491 hasConcept C2777793932 @default.
- W1520073491 hasConcept C2778256501 @default.
- W1520073491 hasConcept C2778629024 @default.
- W1520073491 hasConcept C2778850193 @default.
- W1520073491 hasConcept C2779051857 @default.
- W1520073491 hasConcept C2780580376 @default.
- W1520073491 hasConcept C2780852908 @default.
- W1520073491 hasConcept C2781303535 @default.
- W1520073491 hasConcept C31760486 @default.
- W1520073491 hasConcept C530470458 @default.
- W1520073491 hasConcept C71924100 @default.
- W1520073491 hasConcept C87355193 @default.
- W1520073491 hasConcept C90924648 @default.
- W1520073491 hasConceptScore W1520073491C121332964 @default.
- W1520073491 hasConceptScore W1520073491C121608353 @default.
- W1520073491 hasConceptScore W1520073491C126322002 @default.
- W1520073491 hasConceptScore W1520073491C136948725 @default.
- W1520073491 hasConceptScore W1520073491C141071460 @default.
- W1520073491 hasConceptScore W1520073491C142424586 @default.
- W1520073491 hasConceptScore W1520073491C142724271 @default.
- W1520073491 hasConceptScore W1520073491C197934379 @default.
- W1520073491 hasConceptScore W1520073491C2776694085 @default.
- W1520073491 hasConceptScore W1520073491C2776802502 @default.
- W1520073491 hasConceptScore W1520073491C2777063308 @default.
- W1520073491 hasConceptScore W1520073491C2777793932 @default.
- W1520073491 hasConceptScore W1520073491C2778256501 @default.
- W1520073491 hasConceptScore W1520073491C2778629024 @default.
- W1520073491 hasConceptScore W1520073491C2778850193 @default.
- W1520073491 hasConceptScore W1520073491C2779051857 @default.
- W1520073491 hasConceptScore W1520073491C2780580376 @default.
- W1520073491 hasConceptScore W1520073491C2780852908 @default.
- W1520073491 hasConceptScore W1520073491C2781303535 @default.
- W1520073491 hasConceptScore W1520073491C31760486 @default.
- W1520073491 hasConceptScore W1520073491C530470458 @default.
- W1520073491 hasConceptScore W1520073491C71924100 @default.